Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.59 |
| ▸ | VDR | P11473 | 1/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803342 | 0.88 | SLC9A1 (0.55) | SLC9A1POLBKEAP1GAATSHR | |
| SCHEMBL28569854 | 0.86 | TSHR (0.47) | SLC9A1POLBTSHRNPSR1RXFP1 | |
| SCHEMBL9817222 | 0.86 | CYP2C19 (0.59) | SLC9A1NOD1ALDH3A1HTTL3MBTL1 | |
| SCHEMBL28479855 | 0.84 | TSHR (0.46) | SLC9A1POLBTSHRNPSR1RXFP1 | |
| SCHEMBL11448910 | 0.82 | KMT2A (0.62) | SLC9A1NOD1GAATSHRNPSR1 | |
| SCHEMBL27903206 | 0.82 | KMT2A (0.46) | SLC9A1VDRPOLBTSHRNPSR1 | |
| SCHEMBL7383122 | 0.81 | KMT2A (0.45) | SLC9A1VDRPOLBHTTNPSR1 | |
| SCHEMBL11450935 | 0.81 | SLC9A1 (0.44) | SLC9A1POLBHTTGAATSHR | |
| SCHEMBL30695198 | 0.81 | LMNA (0.48) | SLC9A1POLBHTTGAATSHR | |
| SCHEMBL19136732 | 0.81 | LMNA (0.48) | SLC9A1POLBHTTGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1251120-B1 | ESTERS DERIVED FROM (RR,SS)-2-HYDROXYBENZOATE OF 3-(2-DIMETHYLAMINOMETHYL-1-HYDROXYCYCLOHEXYL)PHENYL | VITA LAB (ES) | 2004-12-08 | — | — | EP | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-3856164-B1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | ACHILLION PHARMACEUTICALS INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-11807627-B2 | Morphic forms of complement factor D inhibitors | Achillon Pharmaceuticals, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20220233673-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2022-07-28 | — | — | US | disclosed |
| EP-3980057-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | Institut Curie (FR) | 2022-04-13 | — | — | EP | disclosed |
| US-20210332026-A1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3856164-A1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | Achillion Pharmaceuticals, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20140221340-A1 | CHEMOKINE RECEPTOR ACTIVITY REGULATOR | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-8729264-B2 | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| WO-2014008236-A1 | PROCESS FOR PREPARING DIASTEREOMERICALLY ENRICHED PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-09 | — | — | WO | disclosed |
| US-20130102620-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2543670-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2206714-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
| CN-1023014-C | Improvements in or relating to ergoline derivatives | LILLY CO ELI (US) | 1993-12-08 | — | — | CN | disclosed |
| CN-1043715-A | The preparation method of ergoline derivatives | LILLY CO ELI (US) | 1990-07-11 | — | — | CN | disclosed |
| US-4242507-A | Sulfonic acid esters | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | SLC9A1 3272/4885VDR 4197/4885NOD1 1516/4885 |
| US-20140221340-A1 | CHEMOKINE RECEPTOR ACTIVITY REGULATOR | CXCR2, ACKR3, CCR2 | SLC9A1 1742/4885VDR 407/4885NOD1 830/4885 |
| US-11807627-B2 | Morphic forms of complement factor D inhibitors | CFD, CFH, CFB | SLC9A1 4745/4885VDR 286/4885NOD1 666/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | SLC9A1 2068/4885VDR 4055/4885NOD1 2305/4885 |
| US-20130102620-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | GRK3, NR3C2, NR1I3 | SLC9A1 1253/4885VDR 41/4885NOD1 2759/4885 |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | SLC9A1 343/4885VDR 3704/4885NOD1 173/4885 |
| US-20210332026-A1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | SLC9A1 4745/4885VDR 286/4885NOD1 666/4885 |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | TYR, CUTA, SERPINB1 | SLC9A1 118/4885VDR 281/4885NOD1 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.